Q-omics provides the consensus-scored TTC21A profile across patient tissues and cancer cell-line models. TTC21A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TTC21A is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, TTC21A RNA expression shows 19,462 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KICH, and ACC as cancer lineages where TTC21A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC21A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC21A survival associations across molecular data types. TTC21A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (11) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC21A RNA expression–survival associations across cancer types. High TTC21A expression shows unfavorable associations in KIRC and ACC, but favorable associations in HNSC, BRCA, UVM and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TTC21A RNA expression.
This table summarizes TTC21A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TTC21A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC21A shows lower tumor expression in KICH, LUAD, LUSC and THCA and higher tumor expression in LIHC and COAD. The KICH box plot shows higher TTC21A RNA expression in normal versus tumor tissue (log2 FC = −1.003, t-test p < 0.001).
This table shows molecular features associated with TTC21A in patient tissues and cancer cell lines. In patient samples, TTC21A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC21A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and CNS.
